AVCN Stock Overview
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.37 |
| 52 Week High | CA$0.60 |
| 52 Week Low | CA$0.23 |
| Beta | 1.53 |
| 1 Month Change | -28.85% |
| 3 Month Change | 8.82% |
| 1 Year Change | -7.50% |
| 3 Year Change | -64.42% |
| 5 Year Change | n/a |
| Change since IPO | -94.06% |
Recent News & Updates
Shareholder Returns
| AVCN | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -11.9% | -8.9% | -1.5% |
| 1Y | -7.5% | 49.0% | 4.7% |
Return vs Industry: AVCN underperformed the Canadian Pharmaceuticals industry which returned 49% over the past year.
Return vs Market: AVCN underperformed the Canadian Market which returned 4.7% over the past year.
Price Volatility
| AVCN volatility | |
|---|---|
| AVCN Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 14.3% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: AVCN's share price has been volatile over the past 3 months.
Volatility Over Time: AVCN's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments.
Avicanna Inc. Fundamentals Summary
| AVCN fundamental statistics | |
|---|---|
| Market cap | CA$36.92m |
| Earnings (TTM) | -CA$8.74m |
| Revenue (TTM) | CA$16.79m |
2.0x
P/S Ratio-3.9x
P/E RatioIs AVCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN income statement (TTM) | |
|---|---|
| Revenue | CA$16.79m |
| Cost of Revenue | CA$10.13m |
| Gross Profit | CA$6.66m |
| Other Expenses | CA$15.40m |
| Earnings | -CA$8.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 39.66% |
| Net Profit Margin | -52.07% |
| Debt/Equity Ratio | 19.5% |
How did AVCN perform over the long term?
See historical performance and comparison